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CDK = cyclin-dependant kinase; EGF = epidermal growth factor; EGFR = epidermal growth factor receptor; HER = human epidermal growth factor
receptor; PI3K = phosphatidyl inositol 3′-kinase; TGF = transforming growth factor.
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Introduction
Since the discovery that the receptor HER2 (erbB2/neu)
was overexpressed in 20–30% of breast cancers, and its
subsequent association with poor prognosis, there has
been much interest in this protein. The production of the
humanised antibody to HER2 (Herceptin [trastuzumab])
and the use of Herceptin to treat patients with HER2 posi-
tive tumours has emphasised the potential of targeted
treatments for breast cancer. The differences between
HER2 and the other members of the type I receptor family
(epidermal growth factor receptor [EGFR], HER3, HER4)
have also been researched. HER2 differs in that it has no
known ligand and when overexpressed HER2 can form
dimers. In contrast the other receptors have several known
ligands that promote dimer formation on binding. HER
receptors can form both homo and heterodimers with
HER2 acting as the preferred dimer partner. The activation
of these receptors either by overexpression or ligand
binding leads to the activation of intracellular growth pro-
moting pathways and thus promotes tumour growth.
Structure of HER receptors and localisation
of downstream elements
A recent paper in Nature [1] reports the crystal structure
of the extracellular region of HER2 alone and in combina-
tion with Herceptin. HER receptors comprise an extracel-
lular region of about 630 amino acids, a single
membrane-spanning region and a cytoplasmic tyrosine
kinase. The extracellular region contains four domains
arranged as a tandem repeat of a two-domain unit consist-
ing of a ~190-amino acid L domain (domains I and III)
followed by a ~120-amino acid cysteine-rich domain
(domains II and IV) [2]. Crystal structures of HER recep-
tors complexed to epidermal growth factor (EGF) or trans-
forming growth factor (TGF)-α, reveal these ligands bound
to domains I and III, and a long finger-like projection from
domain II mediating an inter-receptor dimer. Crystal forms
of non-activated forms of HER3 [2] and HER1 (EGFR) [3]
reveal this finger-like projection from domain II making an
intramolecular contact with domain IV preventing dimerisa-
tion by occluding the dimerisation interface. Binding of
ligand must therefore cause a domain rearrangement,
bringing domains I and III close together and freeing the
domain II projection to participate in dimer formation.
HER2 lacks the domain II-IV contact and the domain I-III
interface appears stable [1]. The HER2 domain arrange-
ment is thus very similar to that observed in other HER
receptors when complexed with ligand. The fact that
HER2 lacks the internal autoinhibitory structure may
explain why it readily forms dimers in the absence of
ligand; in effect it is in the active configuration at all times.
Three papers in Nature Medicine [4,5,6] give an insight
into one way that active HER receptors may promote
tumour growth. Active receptors can stimulate the phos-
phatidyl inositol 3′-kinase (PI3K) signalling pathway via
binding of the p85 subunit of PI3K resulting in activation
of Akt. The Akt kinase inactivates several pro-apoptosis
molecules including Bad, caspase-9, forkhead transcrip-
tion factors, Iκβ kinase and p53 (via MDM2 mediated
phosphorylation). All three papers describe the transloca-
tion of p27 to the cytoplasm when phosphorylated by Akt.
This removes the inhibition of the cyclin dependant kinase,
cyclin-E/CDK2, mediated by nuclear p27. CDK2 is
involved in G1 arrest so this inhibition increases cell prolif-
eration. Cytoplasmic p27 was demonstrated in 41% of
breast cancers [4,5,6] along with activated Akt and this
correlated with poor prognosis [6]. In normal breast tissue
activated Akt was not detected and p27 was nuclear. The
potential link between this mechanism and HER2 activa-
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tion was demonstrated by Shin et al [5] who decreased
activation of Akt by blocking HER2 with Herceptin, result-
ing in increased levels of p27 in the nucleus. Akt can also
be activated via other receptors, and also by Ras activa-
tion, mutational loss of PTEN or activating mutation of Akt
itself, all of which could lead to translocation of p27 and
growth stimulation. Liang et al [6] demonstrated that acti-
vation of Akt renders cells resistant to growth inhibition by
TGF-β and interleukin-6, and that inhibition of the Akt
pathway reverses this effect.
Conclusion
The first 3 papers are of note as they demonstrate the
importance of structural studies to elucidate the action of
proteins. They demonstrate a structural difference
between HER2 and other human epidermal growth factor
receptors (EGFR and HER3) that suggests reasons why
HER2 actively promotes tumour growth. The latter three
papers demonstrate the importance of Akt in breast
cancer with its ability to remove G1 arrest via phosphory-
lation of p27. This can be as a result of stimulation by
receptors (e.g. HER overexpressors) or by other Akt stimu-
latory mechanisms. These papers raise several possibili-
ties for breast cancer therapies; the blocking of Akt could
make cancer cells more sensitive to many growth
inhibitory agents. Designing drugs to target the regions of
HER receptors required for binding may effectively block
some Akt stimulation and therefore tumour growth. Also,
cytoplasmic localisation of p27 could serve as a marker of
HER receptor activation, which may aid in treatment of
HER2 positive tumours. Currently the presence of HER2
overexpression and/or gene amplification is tested for
rather than activity of the receptor and that may in some
part explain the failure of Herceptin in some patients.
These papers provide more information about specific
growth promotion mechanisms in breast tumours and
could help towards producing genetically targeted thera-
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